We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AC Immune (ACIU - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AC Immune is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AC Immune is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACIU's full-year earnings has moved 8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ACIU has returned about 2.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This shows that AC Immune is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Assertio (ASRT - Free Report) . The stock is up 103% year-to-date.
The consensus estimate for Assertio's current year EPS has increased 110.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AC Immune belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #144 in the Zacks Industry Rank. On average, this group has gained an average of 1.6% so far this year, meaning that ACIU is performing better in terms of year-to-date returns.
On the other hand, Assertio belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #91. The industry has moved +1.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on AC Immune and Assertio as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AC Immune (ACIU - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AC Immune is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AC Immune is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ACIU's full-year earnings has moved 8% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ACIU has returned about 2.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This shows that AC Immune is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Assertio (ASRT - Free Report) . The stock is up 103% year-to-date.
The consensus estimate for Assertio's current year EPS has increased 110.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AC Immune belongs to the Medical - Biomedical and Genetics industry, which includes 436 individual stocks and currently sits at #144 in the Zacks Industry Rank. On average, this group has gained an average of 1.6% so far this year, meaning that ACIU is performing better in terms of year-to-date returns.
On the other hand, Assertio belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #91. The industry has moved +1.1% year to date.
Investors interested in the Medical sector may want to keep a close eye on AC Immune and Assertio as they attempt to continue their solid performance.